FOSUN HEALTH Logo

Multiple Myeloma Diagnosis

catalogue

Multiple Myeloma Diagnosis

Multiple Myeloma Diagnosis

Multiple myeloma is diagnosed by putting three findings together: a monoclonal protein that can be measured, plasma cells occupying more than a defined proportion of the marrow, and at least one feature of damage or of near-certain damage. No single one of them is sufficient on its own, and this is why the assessment is a group of tests done at the same time rather than a single decisive examination. The purpose is not only to name the disease but to decide whether it should be treated now.

The blood tests that start the assessment

A group of ordinary blood tests is done first, and although none of them diagnoses myeloma, together they decide how urgent the situation is and what can safely be given:

  • Full blood count — anaemia is the commonest abnormal result, and a low platelet or white cell count indicates heavier marrow involvement.
  • Calcium — a raised level is one of the defining features and needs correcting promptly, because it worsens kidney function and causes confusion and drowsiness.
  • Creatinine and estimated kidney function — determines whether the kidney has been affected, which changes the drugs that can be used and their doses.
  • Albumin and beta-2 microglobulin — the two values from which the international staging system is calculated, which is why they are requested together rather than separately.
  • Lactate dehydrogenase — measured because it is part of the revised staging system and because a high value may indicate disease behaving more aggressively.
  • Immunoglobulins and a urine test — the total immunoglobulin levels show whether the useful antibodies have been suppressed, and urine is examined for light chains that appear there rather than in the blood.

Finding and measuring the monoclonal protein

This is the part of the assessment that is specific to myeloma, and two techniques are used because neither is sufficient alone:

  • Serum protein electrophoresis — separates the proteins in the blood by charge and shows a narrow band where a mixture would normally be, which is the monoclonal protein. It gives a quantity that can be followed over time.
  • Immunofixation — identifies what kind of antibody the band is, since the heavy chain and light chain types matter for how the disease behaves and how it is monitored.
  • Serum free light chain assay — measures the light chains that are not attached to a heavy chain, and reports a ratio between the involved and uninvolved type. It is essential because some patients produce only light chains, and in them electrophoresis looks normal.
  • A 24-hour urine collection, or a serum test in its place, for light chains excreted in the urine — the original way the disease was followed, still used where the serum assay is not available.
  • Repeat measurement is the point of all of them. A single value establishes that the protein exists; the change between values is what measures the response to treatment, so the units and the reference range should always be recorded.

The marrow examination and chromosome testing

The marrow examination answers two questions that the blood tests cannot: how many plasma cells are present, and whether the plasma cells carry the chromosome changes that predict how the disease behaves.

  • The aspirate and the trephine biopsy — the aspirate gives individual cells for counting and for flow cytometry; the core biopsy shows how the plasma cells are distributed, whether they form sheets or clusters, and whether the marrow is fibrotic.
  • A plasma cell proportion of ten percent or more is the usual threshold, though a smaller proportion can be sufficient if a plasmacytoma is present or if the other findings are unequivocal.
  • Flow cytometry identifies which light chain the plasma cells are restricted to and confirms that they are abnormal, and it records the pattern later used to look for residual disease.
  • FISH on the plasma cells — looking for the specific rearrangements and losses described on the overview page, which is different from a standard chromosome analysis because the plasma cells divide too slowly to be seen by that method.
  • The marrow may need repeating — myeloma is patchy, so a sample can under-represent the disease. If the first result is discordant with everything else, a second sample from another site is a reasonable step rather than a contradiction.

Imaging the whole skeleton

Imaging has one job in myeloma: to find and count the areas of bone loss, because their presence defines active disease and their number affects the plan. The choice of method matters more here than in most cancers:

  • Whole-body low-dose CT is generally the imaging of choice, because it shows the lytic lesions that plain X-rays miss and does so quickly, at low radiation dose and cost, over the whole skeleton in one examination.
  • MRI is more sensitive for the marrow itself and for the spine, and is used when compression of the spinal cord is suspected, when the CT is inconclusive, or when the number of lesions needs to be counted precisely.
  • PET-CT is used when disease outside the bone is suspected, and to distinguish active deposits from areas that have already been treated.
  • Plain X-rays and bone scans are both insufficient. X-rays miss lesions that have not destroyed enough bone, and can classify active disease as smouldering; a bone scan using a radioactive tracer detects nothing at all here, because myeloma lesions do not provoke the new bone formation the tracer looks for.

Putting it together into a stage

Once the protein, the plasma cells and the damage are known, the findings are assembled into a stage and a decision:

  • Is there damage or near-certain damage? A calcium level, kidney impairment, anaemia, bone lesions, or one of the three laboratory thresholds decides whether the disease is active. If none is present, the disease is smouldering and is monitored rather than treated.
  • How advanced is it? The international staging system uses beta-2 microglobulin and albumin to place the disease in one of three stages, and the revised version adds the lactate dehydrogenase level and the presence of three particular chromosome findings.
  • What do the chromosomes say? The FISH results determine whether the disease is in a higher-risk group, which affects how intensive the initial treatment should be and how closely the response is monitored.
  • What can the patient tolerate? Age, kidney function, heart function and any other illness decide whether a transplant is realistic, and that decision shapes the whole first-line plan more than the stage does.

Turning the findings into a written plan

Because myeloma is treated over years, the plan that follows diagnosis should state not only what is given but how it will be judged. Three things are worth asking for in writing:

  • The full findings rather than the conclusion — the protein type and value, the light chain ratio with units, the plasma cell proportion, and the chromosome results. Each of these is used again at every subsequent assessment, which is why the numbers matter as much as the diagnosis.
  • The stage and the reason for treatment — which feature placed the disease in the active category, and which stage was assigned. This is the answer to the question "why treat now rather than watch", and it is a legitimate question.
  • The decision points in advance — what will be measured and when, what result would indicate that the current treatment is working, and what would cause a change. Because the sequence of treatments in myeloma depends on the depth of each response, a plan that states its own review points is more useful than one that lists drugs.
  • Fertility and family planning, where relevant, discussed before treatment starts rather than afterwards, since treatment affects it and some options must be arranged in advance.

Frequently Asked Questions

Does one abnormal blood test mean I have myeloma?

No. A monoclonal protein can be found in a small proportion of healthy older adults, and the finding by itself is a monoclonal gammopathy of undetermined significance rather than myeloma. What separates them is whether the protein is above a defined level, whether the marrow contains ten percent or more plasma cells, and whether any damage has occurred. That is why the assessment after such a finding is a group of tests — a repeat protein measurement, a light chain ratio, a blood count, calcium and creatinine, and imaging of the skeleton — rather than an immediate diagnosis.

Why is whole-body CT or MRI used instead of a normal X-ray?

Because a plain X-ray under-reports the disease. A lesion has to destroy a substantial amount of bone before it becomes visible on a plain film, so a patient with several areas of involvement can have an apparently normal skeletal survey. Low-dose CT of the whole body shows those lesions, takes minutes, and covers the whole skeleton in one examination; MRI adds sensitivity in the marrow and the spine, and is the test used when compression of the spinal cord is a concern. Nor is a bone scan useful here, because myeloma lesions do not trigger the new bone formation that a bone scan detects.

How long does the assessment take?

The blood and urine tests are reported within a day or two, the imaging within a few days, and the marrow examination with its flow cytometry within several days. Chromosome testing by FISH on the plasma cells and any molecular tests take longer, because they are performed on selected cells and are reported separately from the routine marrow findings. Most patients therefore have the diagnosis and the first plan within one to two weeks of the assessment beginning — which is appropriate for a disease in which the decision is whether to treat now or to monitor.

Can the diagnosis be made without a bone marrow examination?

Only in a minority of situations. If a plasmacytoma has been biopsied, or if the plasma cells have been confirmed in another tissue, the requirement for a marrow proportion can be satisfied differently. In general, however, the marrow examination is what establishes both the proportion of plasma cells and the chromosome findings, and the chromosome findings are what set the risk group that determines how intensive the treatment should be. A diagnosis stated without them is a diagnosis with its most useful part missing.

Have the protein and marrow results reviewed together

Send the serum protein electrophoresis and immunofixation reports with their values, the free light chain ratio with units, the full blood count, calcium, creatinine and albumin, the marrow aspirate and biopsy reports with the FISH findings, and the imaging report. Our haematology team will return a written assessment within 48 hours of the file being complete.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*